Cell-based products dominate advanced therapy pipeline in EU
This article was originally published in Scrip
Executive Summary
The approval rate for advanced therapy medicinal products (ATMPs) may be slow, but there are many more drugs coming through the R&D pipeline, as evidenced by the level of scientific advice being given by the European Medicines Agency's Committee on Advanced Therapies (CAT), according to Paula Salmikangas, the Finnish researcher who has just been promoted from vice-chair of the committee to chair for a three-year period.